7754.TWO AnnJi Pharmaceutical Co., Ltd.
- Market cap
- TWD 6.94B
- P/E
- -
- P/B
- 16.82x
- ROE
- -111.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7754.TWO undervalued?
Graham numberThe Graham number of AnnJi Pharmaceutical Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AnnJi Pharmaceutical Co., Ltd. fundamental analysis
No fundamental analysis for AnnJi Pharmaceutical Co., Ltd. yet.
AnnJi Pharmaceutical Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AnnJi Pharmaceutical Co., Ltd.
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co.…
Full company profileAnnJi Pharmaceutical Co., Ltd. financial statements
AnnJi Pharmaceutical Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.44M | 1.63M | 144M | 96.4M | 7.55M |
| Gross Profit | 976K | 1.12M | 18.4M | 8.89M | 1.26M |
| Operating Income | -202M | -240M | -269M | -360M | -369M |
| EBITDA | -157M | -195M | -252M | -323M | -311M |
| Net Income | -199M | -237M | -329M | -354M | -358M |
| EPS | -4.39 | -3.61 | -4.25 | -3.81 | -3.78 |
| Balance Sheet | |||||
| Total Assets | 667M | 541M | 1.21B | 1.00B | 590M |
| Total Liabilities | 16.4M | 30.7M | 283M | 340M | 270M |
| Shareholders' Equity | 650M | 511M | 925M | 662M | 320M |
| Cash & Short-term Investments | 391M | 268M | 877M | 706M | 346M |
| Total Debt | 2.79M | - | 61.1M | 55.3M | - |
| Cash Flow | |||||
| Operating Cash Flow | -140M | -189M | -67.2M | -186M | -350M |
| Capital Expenditure | 3.75M | 2.01M | 12.4M | 10.5M | 3.74M |
| Free Cash Flow | -144M | -191M | -79.6M | -197M | -354M |
| Ratios | |||||
| ROE | -30.6% | -46.4% | -35.6% | -53.5% | -111.9% |
| ROA | -29.8% | -43.7% | -27.3% | -35.3% | -60.6% |
| Net Profit Margin | -13,841.5% | -14,554.1% | -229.4% | -367.0% | -4,738.7% |
| Debt to Equity | 0.00x | - | 0.07x | 0.08x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AnnJi Pharmaceutical Co., Ltd. dividends
AnnJi Pharmaceutical Co., Ltd. has not paid dividends in the last 5 fiscal years.
Who owns AnnJi Pharmaceutical Co., Ltd.
Ownership data of AnnJi Pharmaceutical Co., Ltd. is not available yet.
AnnJi Pharmaceutical Co., Ltd. company profile
- Company name
- AnnJi Pharmaceutical Co., Ltd.
- Ticker
- 7754.TWO
- ISIN
- TW0007754004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 16F.-6, No. 508, Sec. 7, Taipei, Taiwan, 115011
- Phone
- 886 2 2365 5677
- Website
- ajpharm.com
About AnnJi Pharmaceutical Co., Ltd.
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
AnnJi Pharmaceutical Co., Ltd. management
4- Dr. Wenying Huang Ph.D.Chairman & CEO
- Mr. Lewis YehChief Financial Officer
- Junyan YeAccounting Supervisor
- Dr. Dennis Huang M.D.Head of Clinical Research & Medical Affairs